Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results [Yahoo! Finance]
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results